Latest Articles
-
By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years?
See the links below for more information and analysis about Abbott: What’s Abbott’s Fundamental Value Based On Expected 2016 Results? What is Abbott’s Revenue And Gross Profit Breakdown? How Has Abbott’s Revenue M...
-
Currency Headwinds Take A Toll On Abbott’s Profitability In Q4: Abbott Earnings
Leading healthcare conglomerate, Abbott Laboratories (NYSE:ABT) posted weak Q4 2015 results on January 28th. Weak guidance for 2016, owing to currency headwinds, and lower than expected EPS of $0.62 induced an approximately 10% drop in the stock...
-
Currency Headwinds Likely To Affect Abbott’s Profitability In Q4’15, Though Further Margin Improvements To Be Expected
Leading medical device maker Abbott Laboratories (NYSE:ABT) is scheduled to report its Q4’15 earnings on January 28th. The company’s revenues in 2015 have been largely affected by currency headwinds throughout the year. However, Abbott saw stron...
-
Scenarios That Can Add To Abbott’s Value
We expect a significant upside to our price estimate for healthcare major Abbott (NYSE: ABT), if it succeeds in getting the FDA approval for commercialization of its fully dissolving heart stent, Absorb, in the U.S. by the end of 2016. Additiona...
-
Abbott’s Q3 Results, A Deeper Look: Strong International Growth and Margin Expansion Drove
Healthcare conglomerate Abbott Laboratories (NYSE:ABT) posted strong third quarter results in its recent release. The company’s underlying growth remains strong despite reported revenues being hammered by currency headwinds. As expected, a bulk o...
-
New Products, Emerging Markets to Drive Abbott’s Q3 Results
Abbott Laboratories (NYSE:ABT) is scheduled to report its third quarter results on October 21st. Despite being on the lookout for acquisition opportunities and investors’ insistence for pulling the trigger, the company’s dry streak in the M&A...
-
Abbott Posts Broadly Positive Results, Currency Headwinds Notwithstanding
Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $5.2 billion, an increase of 2.2% as reported or 10.7% on an operational (constant currency) basis. Adjusting for both currency effects and acquisitions, sales were up by a respecta...
-
How Abbott Sees Potential Gains In Boosting Mylan In Perrigo Takeover Fight ?
Abbott Laboratories (NYSE:ABT) has been on the roll in recent months. March-period earnings were strong, where the worldwide operational sales increased 10% year over year to $4.9 billion with robust growth experience in emerging markets, as we n...
-
Abbott Labs Q1 2015 Earnings: Emerging Markets Drive Growth Across Divisions
Abbott Laboratories (NYSE:ABT) reported another strong quarter on Wednesday, April 22. The company’s worldwide operational sales increased 10% year over year to $4.9 billion with robust growth experienced in emerging markets. The sale of Ab...
-
Abbott Reports Solid Q4 Results On Growth Across Divisions
Healthcare major Abbott Laboratories (NYSE:ABT) reported a strong set of fourth quarter 2014 results on Thursday, January 29. The company’s operational sales from continuing operations increased 10.2% over the prior year quarter to $5.4 bi...
-
Abbott’s Generic Drug Business Gets A Boost With Veropharm Acquisition
Global healthcare major Abbott Laboratories (NYSE:ABT) has completed its acquisition of Russian pharmaceutical company Veropharm for 16.7 billion rubles ($305 million) in an all-cash deal. Veropharm is one of the leading generic drug manufacture...
-
Abbott Looking To Electrophysiology For Medical Device Growth
Abbott Laboratories (NYSE:ABT) recently expanded its medical device business and entered the fast-growing catheter-based electrophysiology market with the acquisition of Topera, Inc. Last month, Abbott entered into an agreement to buy the medical...
-
Abbott Reports Solid Q3 Results On Nutritionals Recovery, Emerging Markets
Healthcare major Abbott Laboratories (NYSE:ABT) reported a strong set of third quarter 2014 results on Wednesday, October 22. The company’s sales from continuing operations increased 6.7% over the prior year quarter to $5.1 billion. Abbott...
-
Abbott Earnings Preview: Nutritionals, Emerging Markets In Focus
Abbott Labs (NYSE:ABT) is scheduled to release its Q3 earnings on Wednesday, October 22. In the previous quarter, operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts’ estimates of $5.52 billion comp...
-
Abbott Looks To Boost Vision Care Product Sales With New Plant In Malaysia
Abbott Laboratories (NYSE:ABT) recently announced that it will invest $60 million in an intraocular lens (IOL) manufacturing plant in Malaysia. IOLs are lenses which are implanted in the eye during the treatment of cataracts. The company expects ...
